Lead Editor:
Dr feng jiang,
fudan university,
China
Around 90% of cancers diagnosed in adults are characterized as solid tumors. These manifest in various regions of the human body, such as the breasts, lungs, prostate, colon, and organs like the bladder and kidneys. Comprising a diverse mix of cells — ranging from cancer cells, cancer stem cells, and connective tissue cells to immune cells — these tumors showcase significant variability across patients. This diversity is often attributed to the variety of activated signaling routes and genetic changes, leading to different prognoses and sometimes even resistance to medications. In the context of recent technological advancements, the broad-scale adoption of multiomics techniques, spanning transcriptomics, epigenomics, metabolomics, proteomics, and microbiomics, has enabled a deeper understanding of the specific traits of each tumor subtype, and even individual patients. These cutting-edge methodologies, paired with algorithms synthesizing varied omics data, pave the way for pinpointing molecular patterns related to solid tumors, furthering the cause of precise clinical treatments. We cordially invite submissions that offer fresh perspectives on solid tumors. While the focus remains on their mechanisms, prognoses, and tailored treatments, we also welcome papers delving into methodologies such as multiomics, single-cell research, or in vivo experiments for this upcoming Special Issue.
Submission deadline:
13/03/2026
|
Views:
